Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses
Open Access
- 12 April 2010
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 149 (3) , 399-409
Abstract
Summary: Acute promyelocytic leukaemia (APL) treatment often includes high cumulative doses of anthracyclines, which can cause long‐term cardiotoxicity. Here, we report the favourable outcome in 81 paediatric APL patients treated according to the consecutive acute myeloid leukaemia‐Berlin/Frankfurt/Muenster (AML‐BFM) trials ‐93/‐98/‐2004 with an anthracycline‐cytarabine regimen in combination with all‐trans‐retinoid acid (ATRA). Outcomes achieved by treatment with a reduced cumulative anthracycline dose (350 mg/m2) were comparable to those reported for studies with higher doses. Five‐year overall survival of the total cohort was 89 ± 4% and event‐free survival (pEFS) was 73 ± 6%. Overall survival was similar when comparing AML‐BFM trial periods (trial 93: 88 ± 8%, 98: 85 ± 7% and 2004: 94 ± 8%, P(logrank) = 0·63). Seventy‐five (93%) patients achieved complete remission. Most fatal events occurred during the first 6 weeks of treatment. Long‐term cardiotoxicity was observed in one patient. Two patients suffered from secondary haematological malignancies. Salvage treatment was effective in 7/9 patients (78%) with relapsed APL, who now are long‐term survivors after second line combination treatment with arsenic trioxide (4/7 patients) and stem cell transplantation (5/7 patients). Our results demonstrate that – combined with ATRA – a lower cumulative anthracycline dose can be used safely to maintain high cure rates and promote the reduction of long‐term sequelae, such as cardiotoxicity in APL patients.Keywords
This publication has 44 references indexed in Scilit:
- Isolated central nervous system relapse in acute promyelocytic leukemia (APL)—responsePediatric Blood & Cancer, 2009
- Central nervous system involvement in relapsed acute promyelocytic leukemiaPediatric Blood & Cancer, 2009
- Precursor T-Lymphoblastic Lymphoma as a Secondary Malignancy in a Young Patient after Successful Treatment of Acute Promyelocytic LeukemiaOnkologie, 2009
- Anthracycline associated cardiotoxicity in survivors of childhood cancerHeart, 2008
- Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AMLPediatric Blood & Cancer, 2006
- Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98Journal of Clinical Oncology, 2006
- GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in childrenBlood, 2005
- Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98Journal of Clinical Oncology, 2004
- Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experienceLeukemia, 2004
- Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93Leukemia, 2001